Valuation: Virbac

Market Cap 286.52Cr 326.78Cr 264.11Cr 247.26Cr 463.65Cr 31TCr 473.28Cr 3.17TCr 1.23TCr 15TCr 1.23TCr 1.2TCr 53TCr P/E 2026 *
17x
P/E 2027 * 15.2x
Enterprise Value 298.62Cr 340.58Cr 275.26Cr 257.7Cr 483.23Cr 32TCr 493.26Cr 3.31TCr 1.28TCr 16TCr 1.28TCr 1.25TCr 55TCr EV / Sales 2026 *
1.93x
EV / Sales 2027 * 1.76x
Free-Float
49.03%
Yield 2026 *
0.51%
Yield 2027 * 0.6%
1 week+0.44%
Current month-4.62%
1 month-6.33%
3 months-3.95%
6 months-2.44%
Current year-4.22%
1 week 332.5
Extreme 332.5
344.5
1 month 327.5
Extreme 327.5
369.5
3 years 241
Extreme 241
394.5
5 years 216.5
Extreme 216.5
441.5
10 years 101.68
Extreme 101.682
441.5
Manager TitleAgeSince
Chief Executive Officer 46 01/09/2025
Chief Executive Officer 50 27/09/2024
Chief Operating Officer 64 01/01/2022
Director TitleAgeSince
Chairman 61 01/04/2006
Director/Board Member 68 28/07/2010
Director/Board Member 65 05/09/2017
Change 5-day change 1-year change 3-year change Capi.($)
-0.15%+0.44%+8.44%+28.73% 326.78Cr
-2.22%-3.33%-51.16%-54.58% 3.19TCr
+0.82%+1.45%+71.82%+148.68% 1.23TCr
-2.32%-7.83%-8.31%+13.79% 399.77Cr
-5.30%-2.80%+46.48%+25.44% 183.77Cr
-2.32%-0.51%-25.06%-4.07% 160.46Cr
-0.44%-0.50%+26.15%+137.38% 128.55Cr
-2.97%-5.39%-24.47%-18.80% 96Cr
+0.70%+4.47%-0.82%-16.78% 96Cr
-1.33%-6.60%-17.27%-48.44% 89Cr
Average -1.71%-2.33%+2.58%+21.13% 618.97Cr
Weighted average by Cap. -1.57%-2.40%-12.16%+6.31%

Financials

2026 *2027 *
Net sales 154.64Cr 176.36Cr 142.54Cr 133.45Cr 250.23Cr 17TCr 255.43Cr 1.71TCr 662.92Cr 8.22TCr 662.25Cr 647.79Cr 29TCr 163.95Cr 186.99Cr 151.13Cr 141.48Cr 265.31Cr 18TCr 270.81Cr 1.82TCr 702.85Cr 8.72TCr 702.14Cr 686.8Cr 30TCr
Net income 17Cr 19Cr 15Cr 14Cr 27Cr 1.8TCr 28Cr 185.05Cr 72Cr 888.12Cr 72Cr 70Cr 3.08TCr 19Cr 22Cr 18Cr 16Cr 31Cr 2.05TCr 31Cr 210.73Cr 82Cr 1.01TCr 81Cr 80Cr 3.51TCr
Net Debt 12Cr 14Cr 11Cr 10Cr 20Cr 1.3TCr 20Cr 134.05Cr 52Cr 643.35Cr 52Cr 51Cr 2.23TCr 2.65Cr 3.02Cr 2.44Cr 2.29Cr 4.29Cr 285.02Cr 4.38Cr 29Cr 11Cr 140.87Cr 11Cr 11Cr 488.46Cr
Logo Virbac
Virbac specializes in the research, production and marketing of veterinary medicines. Net sales break down by family of products as follows: - pet medications (60.7%): pest control drugs, vaccines, antibiotics, anesthetics, anti-inflammatory drugs, mouth/dental care products, ophthalmologic and dermatological products intended for dogs, cats, horses, birds, rodents, etc. The group also offers foods and electronic identification chips; - livestock medications (39.3%): pest control drugs and antibiotics intended for cattle, sheep, pigs, poultry, etc. Net sales are distributed geographically as follows: Europe (41.6%), Latin America (15.2%), North America (13.6%), India/Africa/Middle East (12.2%), Eastern Asia (10.5%) and Pacific (6.9%).
Employees
-
Date Price Change
26/26/26 €340.50 -0.15%
25/26/25 €341.00 +0.74%
24/26/24 €338.50 +1.20%
23/26/23 €334.50 -0.74%
22/26/22 €337.00 -0.59%
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
342.00EUR
Average target price
412.88EUR
Spread / Average Target
+20.72%

Quarterly revenue - Rate of surprise